Scarica l'app Stockscreener
1.51
48.04%
0.49
Dopo l'orario di chiusura:
1.31
-0.20
-13.25%
Precedente Chiudi:
$1.02
Aprire:
$1.71
Volume 24 ore:
136.09M
Relative Volume:
63.98
Capitalizzazione di mercato:
$20.81M
Reddito:
-
Utile/perdita netta:
$-8.83M
Rapporto P/E:
-1.9099
EPS:
-0.7906
Flusso di cassa netto:
$-8.61M
1 W Prestazione:
+46.60%
1M Prestazione:
+43.81%
6M Prestazione:
+23.77%
1 anno Prestazione:
+5.59%
Intervallo 1D:
$1.36
$2.0299
Intervallo di 1 settimana:
$1.00
$2.0299
Portata 52W:
$0.8588
$2.67
Cocrystal Pharma Inc Stock (COCP) Company Profile
Nome
Cocrystal Pharma Inc
Settore
Industria
Telefono
(786) 459-1831
Indirizzo
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.51 | 20.81M | 0 | -8.83M | -8.61M | -0.7906 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-07-08 | Iniziato | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Borsa (COCP) Ultime notizie
COCP PE Ratio & Valuation, Is COCP Overvalued - Intellectia AI
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate - finance.yahoo.com
Shares +48% after hours: COCP Cocrystal Pharma NASDAQ 03 Apr earnings spotlight - Meyka
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988 - Sahm
Cocrystal Pharma (COCP) Receives FDA Fast Track Status for Norov - GuruFocus
Cocrystal Pharma stock surges on FDA Fast Track designation - Investing.com
Cocrystal Pharma stock surges on FDA Fast Track designation By Investing.com - Investing.com Canada
Cocrystal Pharma, Inc. (8CC.F) stock price, news, quote and history - Yahoo Finance UK
Nasdaq Down 1%; US Initial Jobless Claims Fall - Benzinga
Cocrystal Pharma Advances in Norovirus Study as Financial Challenges Loom - StocksToTrade
Cocrystal Pharma Wins FDA Fast Track for Norovirus Drug - TipRanks
COCP Stock Soars 75% — What Is The Link To Cocrystal’s Norovirus Treatment? - Stocktwits
Cocrystal Pharma Advances Antiviral Trials Amid Financial Strategy Shift - timothysykes.com
FDA Fast Track backs Cocrystal (Nasdaq: COCP) oral norovirus antiviral CDI-988 - Stock Titan
Cocrystal Pharma, Inc. announced that its antiviral candidate drug Cdi-988 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). - Bitget
Cocrystal's norovirus pill gets FDA fast track amid 685M yearly cases - Stock Titan
COCP gets FDA Fast Track for CDI-988 norovirus drug, stock up 75% | Tap to know more | Inshorts - inshorts.com
Cocrystal begins norovirus challenge study, reports 2025 results By Investing.com - Investing.com South Africa
Cocrystal Pharma Reports 2025 Financial Results and Advances Norovirus and Influenza Antiviral Drug Pipeline - Minichart
Cocrystal Pharma 2025 Research and Development Expenses $5.1M >COCP - Moomoo
Cocrystal Pharma Reports 2025 Financial Results, Advances Antiviral Drug Programs - National Today
Cocrystal Pharma Reports 2025 Financial Results - National Today
[10-K] Cocrystal Pharma, Inc. Files Annual Report - Stock Titan
Cocrystal begins norovirus challenge study, reports 2025 results - Investing.com
Cocrystal Pharma 2025 10-K: $0 Revenue, $(0.78) EPS, $(8.83)M Net Loss - TradingView
Cocrystal Pharma reports 2025 net loss $8.8M, cash $7.7M, advances norovirus CDI-988 into Phase 1b - TradingView
Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cocrystal Pharma (NASDAQ: COCP) cuts 2025 loss to $8.8M and advances antivirals - Stock Titan
Cocrystal Pharma, Inc. recently released its financial report for fiscal year 2025 and provided an update on the latest progress in its antiviral drug development projects. - Bitget
Cocrystal Pharma 2025 net loss narrows as R&D expenses fall - TradingView
BRIEF-Cocrystal Pharma FY Net Income USD -8.831 Million - TradingView
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewswire
COCP Stock Price, Quote & Chart | COCRYSTAL PHARMA INC (NASDAQ:COCP) - ChartMill
Institution Moves: Can Cocrystal Pharma Inc ride the EV waveEarnings Recap Report & Real-Time Volume Surge Alerts - baoquankhu1.vn
Insider Buy: Is Cocrystal Pharma Inc stock technically oversold2026 Spike Watch & Verified Swing Trading Watchlists - baoquankhu1.vn
Cocrystal Pharma Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
If You Invested $1,000 in Cocrystal Pharma Inc (COCP) - Stock Titan
COCP SEC FilingsCocrystal Pharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Levels: Can Cocrystal Pharma Inc keep up with sector leaders2026 Update & High Conviction Buy Zone Alerts - baoquankhu1.vn
Cocrystal Pharma Announces Passing of Board Member Japour - The Globe and Mail
Cocrystal begins dosing patients in norovirus challenge study - Investing.com Nigeria
Cocrystal Pharma, Inc. Announces Passing of Board Member Dr. Anthony Japour in March 2026 9 - Minichart
Cocrystal Pharma (COCP) reports death of board director Japour - Stock Titan
Why is Cocrystal Pharma Inc stock going up2026 Bull vs Bear & Real-Time Price Movement Reports - baoquankhu1.vn
COCP|Cocrystal Pharma Inc|Price:1.030|Chg%:-0.03 - TradingKey
Cocrystal begins dosing patients in norovirus challenge study By Investing.com - Investing.com South Africa
Can Cocrystal Pharma Inc keep up with sector leadersWall Street Watch & Real-Time Buy Signal Notifications - baoquankhu1.vn
Cocrystal Pharma Doses First Subjects in Phase 1b Trial of CDI-988 Oral Antiviral for Norovirus Prevention and Treatment - Minichart
Cocrystal Pharma Inc Azioni (COCP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cocrystal Pharma Inc Azioni (COCP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | Director |
Feb 06 '26 |
Buy |
0.95 |
50,000 |
47,280 |
1,888,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 31 '25 |
Buy |
0.95 |
50,000 |
47,275 |
1,838,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 30 '25 |
Buy |
0.97 |
20,000 |
19,310 |
1,788,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 26 '25 |
Buy |
0.97 |
40,000 |
38,944 |
1,768,551 |
| FROST PHILLIP MD ET AL | Director |
Dec 24 '25 |
Buy |
0.97 |
25,000 |
24,258 |
1,728,551 |
| FROST PHILLIP MD ET AL | Director |
Nov 26 '25 |
Buy |
0.99 |
4,000 |
3,975 |
1,703,551 |
| FROST PHILLIP MD ET AL | Director |
Nov 25 '25 |
Buy |
0.94 |
20,000 |
18,812 |
1,699,551 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):